Work

Abstract CT253: HERIZON-BTC-302: A phase 3 trial of zanidatamab with standard-of-care therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct253

Authors: James J. Harding, Teresa Macarulla, Xiaotian Wu, Phillip M. Garfin, Takuji Okusaka, Shubham Pant

Institutions: Memorial Sloan Kettering Cancer Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Jazz Pharmaceuticals (United States), National Cancer Center Hospital, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cholangiocarcinoma and Gallbladder Cancer Studies

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409821978

Cites:

Cited by:

Related to: 10